Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 2023;72:338–44.

Article  PubMed  Google Scholar 

Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–67.

Article  CAS  PubMed  Google Scholar 

Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073–87.e3.

Article  CAS  PubMed  Google Scholar 

Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643–9.

Article  CAS  PubMed  Google Scholar 

Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol. 2011;5:385–99.

Article  PubMed  Google Scholar 

Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 1999;59:320–4.

CAS  PubMed  Google Scholar 

Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 1995;55:5548–50.

CAS  PubMed  Google Scholar 

Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J, et al. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem. 1995;270:22044–9.

Article  CAS  PubMed  Google Scholar 

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336–8.

Article  CAS  PubMed  Google Scholar 

David CJ, Massagué J. Contextual determinants of TGF-β action in development, immunity and cancer. Nat Rev Mol Cell Biol 2018;19:419–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity 2019;50:924–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang L, Moses HL. Transforming growth factor-β: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res. 2008;68:9107–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol 2012;13:616–30.

Article  PubMed  PubMed Central  Google Scholar 

López-Casillas F, Wrana JL, Massagué J. Betaglycan presents ligand to the TGF-β signaling receptor. Cell 1993;73:1435–44.

Article  PubMed  Google Scholar 

Heldin CH, Moustakas A. Signaling receptors for TGF-β family members. Cold Spring Harb Perspect Biol. 2016;8:a022053.

Article  PubMed  PubMed Central  Google Scholar 

Jung B, Staudacher JJ, Beauchamp D. Transforming growth factor β superfamily signaling in development of colorectal cancer. Gastroenterology 2017;152:36–52.

Article  CAS  PubMed  Google Scholar 

Hirai R, Fijita T. A human transforming growth factor-beta type II receptor that contains an insertion in the extracellular domain. Exp Cell Res 1996;223:135–41.

Article  CAS  PubMed  Google Scholar 

Rotzer D, Roth M, Lutz M, Lindemann D, Sebald W, Knaus P. Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. EMBO J. 2001;20:480–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konrad L, Scheiber JA, Völck-Badouin E, Keilani MM, Laible L, Brandt H, et al. Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells. BMC Genomics. 2007;8:318.

Article  PubMed  PubMed Central  Google Scholar 

Bertolio MS, La Colla A, Carrea A, Romo A, Canziani G, Echarte SM, et al. A novel splice variant of human TGF-β Type II receptor encodes a soluble protein and its Fc-tagged version prevents liver fibrosis in vivo. Front Cell Dev Biol. 2021;9:690397.

Article  PubMed  PubMed Central  Google Scholar 

Zhang YE. Non-smad signaling pathways of the TGF-β family. Cold Spring Harb Perspect Biol. 2017;9:a022129.

Article  PubMed  PubMed Central  Google Scholar 

Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer 2017;3:56–71.

Article  CAS  PubMed  Google Scholar 

Teixeira AF, Ten Dijke P, Zhu HJ. On-target anti-TGF-β therapies are not succeeding in clinical cancer treatments: what are remaining challenges? Front Cell Dev Biol 2020;8:605.

Article  PubMed  PubMed Central  Google Scholar 

Liu S, Ren J, ten Dijke P. Targeting TGFβ signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6:8.

Article  PubMed  PubMed Central  Google Scholar 

Itatani Y, Kawada K, Fujishita T, Kakizaki F, Hirai H, Matsumoto T, et al. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. Gastroenterology 2013;145:1064–75.e11.

Article  CAS  PubMed  Google Scholar 

Horibata S, Vo TV, Subramanian V, Thompson PR, Coonrod SA. Utilization of the soft agar colony formation assay to identify inhibitors of tumorigenicity in breast cancer cells. J Vis Exp. 2015;99:e52727.

Google Scholar 

Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47:320–9.

Article  CAS  PubMed  Google Scholar 

Akhurst RJ. Targeting TGF-β signaling for therapeutic gain. Cold Spring Harb Perspect Biol. 2017;9:a022301.

Article  PubMed  PubMed Central  Google Scholar 

Hata A, Chen YG. TGF-β signaling from receptors to smads. Cold Spring Harb Perspect Biol. 2016;8:a022061.

Article  PubMed  PubMed Central  Google Scholar 

Fink SP, Mikkola D, Willson JK, Markowitz S. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 2003;22:1317–23.

Article  CAS  PubMed  Google Scholar 

Stolfi C, De Simone V, Colantoni A, Franzè E, Ribichini E, Fantini MC, et al. A functional role for Smad7 in sustaining colon cancer cell growth and survival. Cell Death Dis. 2014;5:e1073.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, Zou C, Zou C, Han Z, Xiao H, Wei H, et al. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting SMAD7. Cancer Lett. 2013;335:168–74.

Article  CAS  PubMed  Google Scholar 

von Gersdorff G, Susztak K, Rezvani F, Bitzer M, Liang D, Böttinger EPSmad3. and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta. J Biol Chem. 2000;275:11320–6.

Article  Google Scholar 

de Ceuninck van Capelle C, Spit M, Ten Dijke P. Current perspectives on inhibitory SMAD7 in health and disease. Crit Rev Biochem Mol Biol. 2020;55:691–715.

Article  PubMed  Google Scholar 

Edlund S, Lee SY, Grimsby S, Zhang S, Aspenström P, Heldin CH, et al. Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol. 2005;25:1475–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang Y, Liu Z, Zhao L, Clemens TL, Cao X. Smad7 stabilizes beta-catenin binding to E-cadherin complex and promotes cell-cell adhesion. J Biol Chem. 2008;283:23956–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lasorella A, Benezra R, Iavarone A. The ID proteins: master regulators of cancer stem cells and tumour aggressiveness. Nat Rev Cancer. 2014;14:77–91.

Article  CAS  PubMed  Google Scholar 

Ullmann P, Rodriguez F, Schmitz M, Meurer SK, Qureshi-Baig K, Felten P, et al. The miR-371∼373 cluster represses colon cancer initiation and metastatic colonization by inhibiting the TGFBR2/ID1 signaling axis. Cancer Res. 2018;78:3793–808.

Article